RecombinantSaccharomyces cerevisiaeExpressing P450 in Artificial Digestive Systems: a Model for Biodetoxication in the Human Digestive Environment
Authors:
Open Access
- 1 May 2003
- journal article
- Published by American Society for Microbiology in Applied and Environmental Microbiology
- Vol. 69 (5) , 2884-2892
Abstract
The use of genetically engineered microorganisms such as bacteria or yeasts as live vehicles to carry out bioconversion directly in the digestive environment is an important challenge for the development of innovative biodrugs. A system that mimics the human gastrointestinal tract was combined with a computer simulation to evaluate the survival rate and cinnamate 4-hydroxylase activity of a recombinant model ofSaccharomyces cerevisiaeexpressing the plant P450 73A1. The yeasts showed a high level of resistance to gastric and small intestinal secretions (survival rate after 4 h of digestion, 95.6% ± 10.1% [n= 4]) but were more sensitive to the colonic conditions (survival rate after 4 h of incubation, 35.9% ± 2.7% [n= 3]). For the first time, the ability of recombinantS. cerevisiaeto carry out a bioconversion reaction has been demonstrated throughout the gastrointestinal tract. In the gastric-small intestinal system, 41.0% ± 5.8% (n= 3) of the ingestedtrans-cinnamic acid was converted intop-coumaric acid after 4 h of digestion, as well as 8.9% ± 1.6% (n= 3) in the stomach, 13.8% ± 3.3% (n= 3) in the duodenum, 11.8% ± 3.4% (n= 3) in the jejunum, and 6.5% ± 1.0% (n= 3) in the ileum. In the large intestinal system, cinnamate 4-hydroxylase activity was detected but was too weak to be quantified. These results suggest thatS. cerevisiaemay afford a useful host for the development of biodrugs and may provide an innovative system for the prevention or treatment of diseases that escape classical drug action. In particular, yeasts may provide a suitable vector for biodetoxication in the digestive environment.Keywords
This publication has 27 references indexed in Scilit:
- The ‘biodrug’ concept: an innovative approach to therapyTrends in Biotechnology, 2001
- A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation productsApplied Microbiology and Biotechnology, 1999
- Lactic acid bacteria as antigen delivery vehicles for oral immunization purposesInternational Journal of Food Microbiology, 1998
- Lactic acid bacteria as vaccine delivery vehiclesAntonie van Leeuwenhoek, 1996
- Cytochromes P450 in Phenylpropanoid MetabolismDrug Metabolism and Drug Interactions, 1995
- Characterization of recombinant plant cinnamate 4‐hydroxylase produced in yeastEuropean Journal of Biochemistry, 1994
- Development of a 5-step multi-chamber reactor as a simulation of the human intestinal microbial ecosystemApplied Microbiology and Biotechnology, 1993
- Disposition kinetics of Saccharomyces boulardii in man and ratBiopharmaceutics & Drug Disposition, 1989
- A model of an ‘artificial stomach’ for assessing the characteristics of an antacidAlimentary Pharmacology & Therapeutics, 1988
- Enzyme-Substitution Therapy with the YeastSaccharomyces cerevisiaein Congenital Sucrase-Isomaltase DeficiencyNew England Journal of Medicine, 1987